慢性乙型肝炎C基因启动子变异与干扰素治疗应答的关系  

RELATIONSHIP BETWEEN THE MUTATIONS IN THE COKE PROMOTOR AND RESPONSE TO INTERFERON TREATMENT IN CHRONIC HEPATITIS B

作　　者：邱望龙 李福元 管岑 潘志灵 黄四邑 

机构地区：[1]广州铁路局中心医院传染科,510080

出　　处：《实用肝脏病杂志》1998年第3期136-138,共3页Journal of Practical Hepatology

摘　　要：目的:乙型肝炎病毒(HBV)C基因启动子(BCP)变异可在转录水平影响HBeAg前体的表达,本文探讨BCP区变异与干扰素治疗的关系。方法:对本院35例慢性乙型肝炎患者干扰素治疗前、后及随访半年105份血清标本进行分析,采用错配PCR-限制性片段长度多态性分析(RFLP)技术检测HBV毒株BCP区核苷酸(nt)1762碱基A→T和1764G→A这一联合点突变。结果:35例慢性乙型肝炎患者在干扰素治疗前检出8例(23％)BCP变异,其中4例干扰素治疗有应答(50％),随访有2例复发(50％),长期应答率为25％,而20例野毒株中有12例有应答(60％),2例复发(17％),长期应答率50％,两组比较有显著性差异(P<0.01。结论:慢性乙型肝炎BCP变异可能是干扰素治疗后复发的一个因素。Objective: The mutation in the basic core promoter (BCP) of hepatitis B virus down-regulate HBeAg precursor expression at the transcriptional level.The relationship between the BCP mutant and interferon treatment was studied.Methods:The 105 serum samples from 35 patients with chonic hepatitis B at pretreatment.posttreatment and at the end of follow-up were analysed in our hospital.The two point mutations at nucleotides(nt) 1762 A and nt 1764 G^A in the BCP region of HBV genomes were detected by combining mismatched polymerase chain reaction (PCR) with restriction fragment length polymorphism assay (RFLP).Results: 8(23% ) of 35 patients with chonic hepatitis B were with mutations in the BCP region at pretreatment, of which 4 were in response to interferon treatment(50%),2 relapsed in the follw-up(50%).The sustained response rate was 25%.12(60%) of 20 cases with wild-type strain infection were in response to interferon.Out of them, 2 (17%) relapsed.The sustained response rate was 50%.Conclusion: The results suggest that the mutations in BCP region may be one of the causes leading to relapse after interferon treatment.

关 键 词：乙型肝炎 基因变异 干扰素 限制性片段长度多态性分析 

分 类 号：R512.6[医药卫生—内科学]